📣 VC round data is live. Check it out!

CareDx Valuation Multiples

Discover revenue and EBITDA valuation multiples for CareDx and similar public comparables like Eckert & Ziegler, JMDC, Vazyme Biotech, Omada Health and more.

CareDx Overview

About CareDx

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.


Founded

1998

HQ

United States

Employees

765

Website

caredx.com

Financials (LTM)

Revenue: $410M
EBITDA: $40M

EV

$955M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CareDx Financials

CareDx reported last 12-month revenue of $410M and EBITDA of $40M.

In the same LTM period, CareDx generated $285M in gross profit, $40M in EBITDA, and had net loss of ($13M).

Revenue (LTM)


CareDx P&L

In the most recent fiscal year, CareDx reported revenue of $380M and EBITDA of $32M.

CareDx is unprofitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 8%, and net margin of (6%).

See analyst estimates for CareDx
LTMLast FY202320242025202620272028
Revenue$410M$380M$280M$334M$380M
Gross Profit$285M$257M$178M$224M$257M
Gross Margin70%68%64%67%68%
EBITDA$40M$32M($85M)($34M)($5M)
EBITDA Margin10%8%(30%)(10%)(1%)
EBIT Margin(5%)(7%)(37%)(16%)(7%)
Net Profit($13M)($21M)($190M)$53M($21M)
Net Margin(3%)(6%)(68%)16%(6%)

Financial data powered by Morningstar, Inc.

CareDx Stock Performance

CareDx has current market cap of $1B, and enterprise value of $955M.

Market Cap Evolution


CareDx's stock price is $21.63.

CareDx share price increased by 4.0% in the last 30 days, and by 27.3% in the last year.

CareDx has an EPS (earnings per share) of $-0.41.

See more trading valuation data for CareDx
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$955M$1B0.3%4.0%15.3%27.3%$-0.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CareDx Valuation Multiples

CareDx trades at 2.3x EV/Revenue multiple, and 24.1x EV/EBITDA.

See NTM and 2027E valuation multiples for CareDx

EV / Revenue (LTM)


CareDx Financial Valuation Multiples

As of May 23, 2026, CareDx has market cap of $1B and EV of $955M.

CareDx has a P/E ratio of (87.1x).

LTMLast FY202320242025202620272028
EV/Revenue2.3x2.5x3.4x2.9x2.5x
EV/EBITDA24.1x30.1x(11.2x)(28.1x)(205.1x)
EV/EBIT(44.6x)(38.1x)(9.1x)(17.8x)(38.1x)
EV/Gross Profit3.3x3.7x5.4x4.3x3.7x
P/E(87.1x)(52.3x)(5.9x)21.3x(52.3x)
EV/FCF—26.9x(34.6x)30.2x26.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CareDx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CareDx Margins & Growth Rates

CareDx grew revenue by 20% and EBITDA by 63% in the last fiscal year.

In the most recent fiscal year, CareDx reported gross margin of 68%, EBITDA margin of 8%, and net margin of (6%).

See estimated margins and future growth rates for CareDx

CareDx Margins

Last FY202420252026202720282029
Gross Margin68%67%68%71%
EBITDA Margin8%(10%)(1%)11%
EBIT Margin(7%)(16%)(7%)(2%)
Net Margin(6%)16%(6%)0%
FCF Margin9%9%9%—

CareDx Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth20%19%14%20%
Gross Profit Growth27%26%14%27%
EBITDA Growth63%(60%)(86%)(1212%)
EBIT Growth(73%)(49%)(53%)(73%)
Net Profit Growth(102%)(128%)(141%)(102%)
FCF Growth—(214%)12%—

Data powered by FactSet, Inc. and Morningstar, Inc.

CareDx Operational KPIs

CareDx's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.

CareDx's Rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CareDx's Rule of X is 61% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for CareDx
LTMLast FY202320242025202620272028
Rule of 4023%31%———
Bessemer Rule of X44%61%———
Revenue per Employee—$0.5M———
Opex per Employee—$0.4M———
S&M Expenses to Revenue26%27%30%24%27%
G&A Expenses to Revenue26%28%42%37%28%
R&D Expenses to Revenue18%19%29%22%19%
Opex to Revenue—74%101%83%74%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

CareDx Competitors

CareDx competitors include Eckert & Ziegler, JMDC, Vazyme Biotech, Omada Health, Indegene, OPKO Health, Azenta, Novogene, Bayzed Health Group and Personalis.

Most CareDx public comparables operate across Diagnostics & Genomics, Health Data & Analytics, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Eckert & Ziegler2.8x2.8x9.2x9.4x
JMDC4.9x3.9x17.6x14.7x
Vazyme Biotech4.4x4.2x41.9x27.0x
Omada Health3.0x2.7x121.5x72.5x
Indegene3.1x3.0x16.2x16.6x
OPKO Health1.7x1.8x(24.7x)(7.8x)
Azenta1.0x1.0x9.2x9.7x
Novogene2.1x2.0x13.3x13.4x

This data is available for Pro users. Sign up to see all CareDx competitors and their valuation data.

Start Free Trial

CareDx M&A Activity

CareDx has acquired 10 companies to date.

Last acquisition by CareDx was on April 27th 2026. CareDx acquired Naveris for $160M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by CareDx

Naveris
MediGO
MedActionPlan
Transplant Hero
Description
Naveris is a biotechnology firm based in Waltham, Massachusetts, founded in 2017 that develops blood-based tests for early cancer detection using 3D biomimetic tissue models. Its NavDX assay analyzes circulating tumor-derived DNA fragments to assess head and neck cancer recurrence with high sensitivity in asymptomatic patients post-treatment. Naveris replicates tumor microenvironments ex vivo to support precision oncology trials, matching therapies to patient profiles through partnerships with academic centers like Johns Hopkins. The technology enables real-time monitoring during immunotherapy and chemotherapy regimens.
MediGO is a centralized logistics platform designed for hospitals to manage time-critical medical assets like ventilators, PPE, and infusion pumps through real-time visibility. Headquartered in Tel Aviv, Israel, the company leverages machine learning algorithms to deliver precise estimated times of arrival and optimize resource allocation across facilities. MediGO serves major healthcare networks in the United States and Europe, enabling care teams to coordinate with suppliers and internal stakeholders via a unified dashboard. Launched in 2020 amid the COVID-19 crisis, it expanded from emergency equipment sharing to comprehensive supply chain oversight, reducing delays and waste in operating rooms and ICUs worldwide.
MedActionPlan is a digital platform dedicated to medication management for solid organ transplant recipients. It delivers personalized schedules, adherence tracking, safety alerts, and educational resources to patients and coordinators, reducing complications through proactive monitoring.
Transplant Hero is a Nashville-based mobile app developer providing medication adherence tools for organ transplant recipients. Released in 2015, the app features reminders, logging, and lab trackers synced with Epic EHR systems, used by 10,000 patients across U.S. centers like Vanderbilt. It includes gamification for compliance rates above 95 percent.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Boston, MA
Baltimore, MD
Peapack, NJ
New York City, NY
Deal Date27 Apr 202625 Jul 202310 Nov 20218 Jun 2021
Valuation$160Mundisclosed$4Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all CareDx acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CareDx

When was CareDx founded?CareDx was founded in 1998.
Where is CareDx headquartered?CareDx is headquartered in United States.
How many employees does CareDx have?As of today, CareDx has over 765 employees.
Who is the CEO of CareDx?CareDx's CEO is John Walter Hanna.
Is CareDx publicly listed?Yes, CareDx is a public company listed on Nasdaq.
What is the stock symbol of CareDx?CareDx trades under CDNA ticker.
When did CareDx go public?CareDx went public in 2014.
Who are competitors of CareDx?CareDx main competitors include Eckert & Ziegler, JMDC, Vazyme Biotech, Omada Health, Indegene, OPKO Health, Azenta, Novogene, Bayzed Health Group, Personalis.
What is the current market cap of CareDx?CareDx's current market cap is $1B.
What is the current revenue of CareDx?CareDx's last 12 months revenue is $410M.
What is the current revenue growth of CareDx?CareDx revenue growth (NTM/LTM) is 14%.
What is the current EV/Revenue multiple of CareDx?Current revenue multiple of CareDx is 2.3x.
Is CareDx profitable?Yes, CareDx is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of CareDx?CareDx's last 12 months EBITDA is $40M.
What is CareDx's EBITDA margin?CareDx's last 12 months EBITDA margin is 10%.
What is the current EV/EBITDA multiple of CareDx?Current EBITDA multiple of CareDx is 24.1x.
How many companies CareDx has acquired to date?As of May 2026, CareDx has acquired 10 companies.
What was the largest acquisition by CareDx?$160M acquisition of Naveris on 27th April 2026 was the largest M&A CareDx has done to date.
What companies CareDx acquired?CareDx acquired Naveris, Allenex, ImmuMetrix, OTTR Chronic Care Solutions, MedActionPlan, TransChart, MediGO, BFS Molecular, XynManagement, and Transplant Hero.
In how many companies CareDx has invested to date?CareDx hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to CareDx

Lists including CareDx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial